A dose-finding design for phase I clinical trials based on Bayesian stochastic approximation

被引：0

作者：

Jin Xu

Dapeng Zhang

Rongji Mu

机构：

[1] School of Statistics,

[2] East China Normal University,undefined

[3] Key Laboratory of Advanced Theory and Application in Statistics and Data Science - MOE,undefined

[4] East China Normal University,undefined

[5] Clinical Research Center,undefined

[6] Shanghai Jiao Tong University School of Medicine,undefined

来源：

BMC Medical Research Methodology | / 22卷

关键词：

Adaptive design; Dose-finding; Maximum tolerated dose; Stochastic approximation;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 71 条

[1]

Zhou H(2018)Accuracy, safety, and reliability of novel phase I trial designs Clin Cancer Res. 24 4357-64

[2]

Yuan Y(1989)Design and analysis of phase I clinical trials Biometrics. 45 925-37

[3]

Nie L(1999)Operating characteristics of the standard phase I clinical trial design Comput Stat Data Anal. 30 303-15

[4]

Storer BE(2009)Dose escalation methods in phase I cancer clinical trials J Natl Cancer Inst. 101 708-20

[5]

Reiner E(1990)Continual reassessment method: a practical design for phase I clinical trials in cancer Biometrics. 46 33-48

[6]

Paoletti X(1998)Cancer Phase I Clinical Trials: efficient dose escalation with overdose control Stat Med. 17 1103-20

[7]

O’Quigley J(2010)Dose Finding with Escalation with Overdose Control (EWOC) in Cancer Clinical Trials Stat Sci. 25 217-26

[8]

Le Tourneau C(2008)Critical aspects of the Bayesian approach to phase I cancer trials Stat Med. 27 2420-39

[9]

Lee JJ(2010)A modified toxicity probability interval method for dose-finding trials Clin Trials. 7 653-63

[10]

Siu LL(2017)A Bayesian interval dose-finding design addressing Ockham’s razor: mTPI-2 Contemp Clin Trials. 58 23-33